Aurobindo Pharma Ltd Q4 FY26 Earnings Analysis

- US business expected to grow steadily with product launches; approximately 9% growth ex-gRevlimid in US sales (page 8). - Oral solids US segment (~$1 billion base) growth challenging in percentage terms but Lannett acquisition could create synergies for better business (page 21). - Injectable sales up 17% YoY with expectations of continued double-digit growth next year, pending resolution of FDA warning letter (pages 7-8). - European business showing strong momentum with 27% YoY growth, targeting to exceed €1 billion revenue by end FY26, with further growth from increased supply from China (pages 5-6). - Pen-G and 6APA ramp-up to 65-70% by March 2026, expected to uplift profitability and margins (page 5). - New product launches: 9 products launched last quarter with similar trend expected; significant injectable pipeline filings underway (pages 6, 20). - Dayton US facility commercial from FY27; expected to contribute significantly to revenues (page 6).

- EBITDA margin target for FY26 is expected to be on the higher side of 20% to 21%, reflecting strong earnings growth visibility. - Pen-G facility is breaking even as of Q3 FY26, with expected meaningful EBITDA contribution and improved profitability from Q1 FY27 onwards. - US business growth anticipated with new launches (about 9 per quarter) and growing injectable sales; US oral solids base around $1 billion, expecting growth but difficult to maintain double-digit percentage growth. - European business growing in low double digits (constant currency), with increasing supply from China improving cost efficiency and margins. - Biologics CapEx focused on TheraNym CDMO business (~$120-130 million) with expected moderate investments through FY27. - Overall margins expected to improve with business scale-up; next fiscal year margins likely similar or better than the current year. - R&D and product pipeline investments continue, supporting long-term sustainable growth and profitability.

- Ongoing biologics CapEx for CDMO business (TheraNym) totals around USD 120-130 million over last 7 quarters, with an additional USD 80-120 million expected over next two years to complete these projects (Pages 19-20). - No plans for major greenfield projects beyond biologics; future capital allocation to focus on bolt-on acquisitions fitting strategy (Pages 16, 19). - Net capex for Q4 FY25 was USD 79 million aimed at enhancing manufacturing capabilities, compliance, and automation (Page 5). - CapEx for the new Pen-G facility under implementation to ramp up production, expected to break even in Q4 FY26 and contribute significantly from FY27 onwards (Pages 10, 21). - Lannett acquisition is pending FTC approval, expected to close in Q1 FY27; this will create synergies and help US growth (Pages 10, 21). - No specific CapEx number disclosed for future beyond these, management will consider opportunities as per strategic fit and market conditions (Pages 16, 19, 21).

- There is no specific mention of any immediate or planned new fundraising through debt or equity in the transcript. - The company stated it is not planning for any major greenfield CapEx beyond biologics (USD 150-200 million) and is open to acquisitions if targets fit strategy and come at the right price. - Capital allocation focus remains on strategic acquisitions, CapEx for biologics/CDMO business, dividends, and prudent capital management. - No urgency or definite plans to raise additional capital were indicated. - Management highlighted a cautious approach toward capital allocation and continuing to evaluate inorganic opportunities without immediate need for fundraising.

The transcript provided does not contain explicit information regarding the current or expected order book or pending orders for Aurobindo Pharma Limited as of February 2026. However, some relevant points implying demand and growth outlook include: - Strong business momentum in Europe and stable US business with growth market operations. - U.S. Oral Solid segment stable with healthy demand and recent product launches. - Injectable sales growing year-on-year by 17%. - Several new product launches and regulatory approvals enhancing the pipeline. - Expansion in key growth markets such as Canada, Mexico, and Brazil. - Expect significant ramp-up from the Dayton facility in the US starting FY27. - Growth to be driven by multiple initiatives including differentiated product portfolio and pipeline launches. No specific backlog or pending order quantities or values are disclosed in the call transcript.